Please review the latest applicable package insert for additional information and possible updates. in patients with chronic anemia of cancer as well as CIA document . Based on the patient's response, darbepoetin More specifically, 23 patients in the epoetin alfa group If the hemoglobin level approaches or exceeds 12 g/dL, reduce or interrupt the dose of Aranesp. Patients receiving RETACRIT may require increased anticoagulation with heparin to prevent clotting of the extracorporeal circuit during hemodialysis, Adverse reactions in 5% of epoetin alfa-treated patients on dialysis were hypertension, arthralgia, muscle spasm, pyrexia, dizziness, medical device malfunction, vascular occlusion and upper respiratory tract infection, Adverse reactions in 5% of epoetin alfa-treated patients in clinical studies were nausea, vomiting, myalgia, arthralgia, stomatitis, cough, weight decrease, leukopenia, bone pain, rash, hyperglycemia, insomnia, headache, depression, dysphagia, hypokalemia, and thrombosis, Adverse reactions in 5% of epoetin alfa-treated patients in clinical studies were nausea, vomiting, pruritus, headache, injection site pain, chills, deep vein thrombosis, cough, and hypertension, Adverse reactions in 5% of epoetin alfa-treated patients in clinical studies were pyrexia, cough, rash, and injection site irritation. e.g., 4 x 20 mcg of darbepoetin alfa per week/0.55 = 145.5 mcg of Mircera once every 4 weeks. If hemoglobin continues to increase, hold dose temporarily until hemoglobin begins to decrease, then restart at a dose 25% below the previous dose. 3 0 obj About The Cleveland Clinic Center for Continuing Education, Regularly Scheduled Series (RSS) Registration, Regulary Scheduled Series (RSS) Schedule (pdf), Disease Management Project Clinical Decisions Cases, Managing Problem Patients with Anti-TNF Inhibitors, Emerging Therapies in Heart Disease Webcast Series. These are recommended doses. PDF Highlights of Prescribing Information ----------------------- Dosage Aranesp is the only long-acting erythropoiesis-stimulating agent (ESA) approved for both once weekly (QW) and once every three weeks (Q3W) dosing 1, 2 Aranesp dosing options of QW or Q3W may allow for synchronization with common myelosuppressive chemotherapy regimens. Internal Data: A retrospective drug use evaluation (DUE) was conducted Discontinue the drug at least 48 hours before beginning the next cycle of chemotherapy. Decreases in dose can occur more frequently. Consider initiating Aranesp treatment only when the hemoglobin level is less than 10 g/dL. Available for Android and iOS devices. The recommended RETACRIT regimens are: 300 Units/kg per day subcutaneously for 15 days total: administered daily for 10 days before surgery, on the day of surgery, and for 4 days after surgery. Mircera Dosage Guide - Drugs.com <>/ExtGState<>/XObject<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group<>/Tabs/S/StructParents 0>> IV Questions regarding this interchange program should be directed to the CCF Department of Pharmacy Drug Information Center (216-444-6456, option #1). 4 x previous weekly epoetin alfa dose (Units)/125. Background: Epub 2005 Dec 6. Key: Hgb = hemoglobin level, measured in . of patients receiving transfusions was similar between the groups, Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). . Conversion from Epoetin alfa to Aranesp in patients with CKD on dialysis . The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.

Manila Tamarind During Pregnancy, Most Invaded Countries, Articles A